Physician profile
Moustafa M Eldick
NPI 1962592907
$5,373.21
in general payments reported to CMS, 2019-2025
36 companies · $569 in 2025
The $569 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $452 · 2020: $807 · 2021: $1,048 · 2022: $976 · 2023: $907 · 2024: $614 · 2025: $569.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,090.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,089.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,461.14 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $646.60 | 2019-2025 | |
| Sunovion Pharmaceuticals INC. | $574.29 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $348.35 | 2020-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $278.02 | 2019-2024 | Farxiga, Airsupra |
| Lilly USA, LLC | $180.43 | 2019-2025 | Zepbound |
| Medtronic, INC. | $179.08 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $177.51 | 2021-2023 | |
| Novo Nordisk INC | $175.25 | 2020-2025 | Ozempic, Wegovy |
| Pfizer INC. | $173.13 | 2019-2021 | |
| Allergan, INC. | $128.12 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $122.94 | 2022-2023 | Austedo |
| Sumitomo Pharma America, INC. | $116.27 | 2023-2024 | Gemtesa, Aptiom |
| Novartis Pharmaceuticals Corporation | $80.61 | 2019-2020 | |
| Mylan Specialty L.P. | $78.43 | 2020-2022 |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Moustafa Eldick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.